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In most cell types, mitochondria exist as a branched, 
tubular network. The structural and functional integrity of 
the network is maintained by its continuous fission and 
fusion [1, 2]. Fission segregates functional (polarised) 
parts of the network from dysfunctional (depolarised) 
parts, enabling the clearance of dysfunctional mitochondria 
by mitophagy. Fission is catalysed by Drp1 (dynamin-
related protein1), which is recruited to mitochondria from 
the cytoplasm. Fusion joins the functional mitochondria 
with each other and with the existing network. Fusion is 
mediated by Mitofusin-1/2 (MFN-1/2) and OPA1 (Optic 
atrophy type 1) which catalyse the merger of the outer 
and inner membranes of mitochondria, respectively. 
These processes, collectively known as ‘mitochondrial 
dynamics’, are essential to sustain the bioenergetic, 
biosynthetic and signalling functions of mitochondria. 
Failure to balance the fission and fusion activities is 
implicated in a number of age-related and other oxidative 
stress-associated human diseases, including cancer [1, 2].
Mitochondrial dynamics not only contribute to 
mitochondrial quality control, but play a crucial role 
in normal cell division [1]. In the G1/S phase of the 
cell cycle, mitochondria exist as a branched network to 
ensue efficient ATP supply for cell proliferation. In the S/
G2 phase, Drp1 is phosphorylated by cyclin-dependent 
kinase-1, promoting its recruitment to the mitochondrial 
network, and the subsequent fragmentation. Thus by 
reducing the complexity of the mitochondrial network, 
fission enables equal distribution of mitochondria between 
the daughter cells. It is therefore not surprising that 
genetic inactivation of any of the proteins associated with 
mitochondrial dynamics is embryonic lethal [1]. 
Mitochondrial dynamics have been implicated in 
cancer cell proliferation as well as migration. In most 
cancer cells, mitochondria are fragmented [1, 2]. This 
was attributed to the increased expression or activation 
of Drp1, coupled with the downregulation of MFN-
2. Inhibition of Drp1 and overexpression of MFN2 
prevented abnormal cell proliferation, and intriguingly 
also increased spontaneous apoptosis [1, 2]. A recent study 
demonstrated that stimulation of oncogenic K-Ras induces 
Erk1/2-mediated phosphorylation of Drp1 and subsequent 
mitochondrial fragmentation in pancreatic cancer [1]. 
Mitochondrial dynamics play a role in tumour cell 
migration [1]. Increased Drp1 activity enables smaller 
mitochondria to move along the microtubules to the 
leading edge (lamellipodia) of migrating cells. Presence 
of adequate number of mitochondria at the leading edge 
ensures ATP supply to processes (focal adhesion and 
actin dynamics) essential for cell migration. Inhibition 
of Drp1 prevented mitochondria migration as well as cell 
migration, suggesting that fission is a prerequisite for 
efficient translocation of mitochondria [1]. 
Thus Drp1 plays a central role in mitochondrial 
fragmentation linked to most important hallmarks of 
cancer: abnormal cell proliferation and unwarranted cell 
migration [1]. Increased mitochondrial fragmentation is 
also a fundamental feature of a number of other human 
diseases including diabetes, and cardiovascular (e.g. 
ischemia) and neuronal (Parkinson’s, Alzheimer’s and 
stroke) diseases [2]. Thus there has been considerable 
focus on Drp1. Drp1 activity and its recruitment to 
mitochondria are regulated by a remarkable number 
of signals that modify the protein in multiple ways 
(phosphorylation, ubiquitination, nitrosylation, acetylation 
and sumoylation) [1]. Recent studies have added three 
more players to the already known long list of regulators 
of mitochondrial fission: the TRPM2 (transient receptor 
potential melastatin2) ion channel, lysosomes and Zn2+ [3, 
4]. 
The authors of these new studies showed that 
inhibition of TRPM2 channels prevents oxidative stress 
(high glucose or free fatty acid)-induced mitochondrial 
fragmentation in human endothelial cells and pancreatic 
β-cells, revealing a previously unappreciated mechanism 
[3, 4]. Oxidative stress increases the cellular levels of 
reactive oxygen species (ROS), leading to the activation 
of TRPM2 channels, extracellular Ca2+ entry, Ca2+-induced 
lysosomal Zn2+ release and the subsequent entry of free 
Zn2+ into mitochondria. Rise in mitochondrial Zn2+ causes 
a loss of mitochondrial membrane potential, resulting 
in mitochondrial Drp1 recruitment and fragmentation. 
Given that ROS increase is a hallmark of most cancer 
cells [5], and ROS-sensitive TRPM2 channels are 
upregulated in some cancers (http://www.proteinatlas.org/
ENSG00000142185-TRPM2/cancer), it seems reasonable 
to speculate that a similar mechanism might contribute to 
the increased mitochondrial fragmentation in cancer cells. 
If true, this mechanism could provide the fundamental 
missing link between increased ROS and mitochondrial 
fragmentation in cancer cells.
Several recent studies provide circumstantial support 
for such speculation. RNAi-mediated silencing of TRPM2 
channels prevents prostate cancer cell (PC-3) proliferation 
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[6] and migration [5]. Ca2+ is well known for its signalling 
role in cancer cell proliferation and migration [7]. Zn2+ has 
also been implicated in oxidative stress-induced cancer 
cell migration [5]. 
Mitochondrial dynamics is an attractive drug target 
for cancer as well as a host of other diseases, mentioned 
above. Many of the players in mitochondrial dynamics 
are deemed unsuitable or less safe for development 
of therapeutics. However, despite the fact that genetic 
inactivation of Drp1 is embryonic lethal [1], Drp1 has been 
targeted for drug development. Indeed pharmacological 
inhibition of Drp1 with mdivi1 showed considerable 
promise in preclinical studies of cancer and other diseases 
[8]. Remarkably, however, the beneficial effect of mdivi1 
does not appear to be conferred by its ability to inhibit 
Drp1, but rather owing to the inhibition of mitochondrial 
complex 1 [8]. Given ion channels are excellent drug 
targets, the new findings imply that targeting TRPM2 
channels for cancer and other mitochondrial dynamics-
associated diseases may represent a promising therapeutic 
approach.
Asipu Sivaprasadarao: School of Biomedical Sciences, 
Faculty of Biological Sciences, Multidisciplinary 
Cardiovascular Research Centre, University of Leeds, 
Leeds, UK
Correspondence to: Asipu Sivaprasadarao, email 
a.sivaprasadarao@leeds.ac.uk
Keywords: mitochondrial dynamics, TRPM2, reactive oxygen 
species, calcium, zinc
Received: September 05, 2017
Published: September 30, 2017
REFERENCES
1. Senft D, et al. Curr Opin Cell Biol. 2016; 39:43-52.
2. Archer SL, et al. N Engl J Med. 2013; 369:2236-2251.
3. Abuarab N, et al. Sci Signal. 2017; 10.
4. Li F, et al. Cell Death Differ. 2017; 
 https://doi.org/10.1038/cdd.2017.118.
5. Li F, et al. J Cell Sci. 2016; 129:2016-2029.
6. Zeng X, et al. Prostate Cancer Prostatic Dis. 2010; 13:195-
201.
7. Prevarskaya N, et al. Nat Rev Cancer. 2011; 11:609-618.
8. Bordt EA, et al. Developmental Cell. 2017; 40:583-594 
e586.
Copyright: Sivaprasadarao et al. This is an open-access article 
distributed under the terms of the Creative Commons Attribution 
License 3.0 (CC BY 3.0), which permits unrestricted use, distri-
bution, and reproduction in any medium, provided the original 
author and source are credited.
